WallStreetZenWallStreetZen

NASDAQ: ACRS
Aclaris Therapeutics Inc Stock

$14.05-0.28 (-1.95%)
Updated Feb 3, 2023
ACRS Price
$14.05
Fair Value Price
$14.97
Market Cap
$936.90M
52 Week Low
$9.84
52 Week High
$18.96
P/E
-10.89x
P/B
4.26x
P/S
44.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.50M
Earnings
-$82.08M
Gross Margin
50.7%
Operating Margin
-349.26%
Profit Margin
-349.3%
Debt to Equity
0.22
Operating Cash Flow
-$66M
Beta
0.99
Next Earnings
Feb 22, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ACRS Overview

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ACRS ($14.05) is undervalued by 6.17% relative to our estimate of its Fair Value price of $14.97 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACRS ($14.05) is not significantly undervalued (6.17%) relative to our estimate of its Fair Value price of $14.97 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACRS due diligence checks available for Premium users.

Be the first to know about important ACRS news, forecast changes, insider trades & much more!

ACRS News

Valuation

ACRS fair value

Fair Value of ACRS stock based on Discounted Cash Flow (DCF)
Price
$14.05
Fair Value
$14.97
Undervalued by
6.17%
ACRS ($14.05) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACRS ($14.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ACRS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-10.89x
Industry
10.7x
Market
15.09x

ACRS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.26x
Industry
5.11x
ACRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ACRS's financial health

Profit margin

Revenue
$19.0M
Net Income
-$20.0M
Profit Margin
-104.9%
ACRS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ACRS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$267.6M
Liabilities
$47.8M
Debt to equity
0.22
ACRS's short-term assets ($256.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACRS's short-term assets ($256.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACRS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.8M
Investing
$1.2M
Financing
-$11.0k
ACRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ACRS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ACRS$936.90M-2.28%-10.89x4.26x
ALBO$930.52M-0.80%-6.69x9.30x
PRTC$960.95M0.00%-15.90x1.62x
KURA$895.08M-1.57%-6.56x2.13x
KNSA$980.40M+0.99%6.84x2.55x

Aclaris Therapeutics Stock FAQ

What is Aclaris Therapeutics's quote symbol?

NASDAQ: ACRS) Aclaris Therapeutics trades on the NASDAQ under the ticker symbol ACRS. Aclaris Therapeutics stock quotes can also be displayed as NASDAQ: ACRS.

If you're new to stock investing, here's how to buy Aclaris Therapeutics stock.

What is the 52 week high and low for Aclaris Therapeutics (NASDAQ: ACRS)?

(NASDAQ: ACRS) Aclaris Therapeutics's 52-week high was $18.96, and its 52-week low was $9.84. It is currently -25.89% from its 52-week high and 42.78% from its 52-week low.

How much is Aclaris Therapeutics stock worth today?

(NASDAQ: ACRS) Aclaris Therapeutics currently has 66,683,191 outstanding shares. With Aclaris Therapeutics stock trading at $14.05 per share, the total value of Aclaris Therapeutics stock (market capitalization) is $936.90M.

Aclaris Therapeutics stock was originally listed at a price of $11.05 in Oct 7, 2015. If you had invested in Aclaris Therapeutics stock at $11.05, your return over the last 7 years would have been 27.15%, for an annualized return of 3.49% (not including any dividends or dividend reinvestments).

How much is Aclaris Therapeutics's stock price per share?

(NASDAQ: ACRS) Aclaris Therapeutics stock price per share is $14.05 today (as of Feb 3, 2023).

What is Aclaris Therapeutics's Market Cap?

(NASDAQ: ACRS) Aclaris Therapeutics's market cap is $936.90M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aclaris Therapeutics's market cap is calculated by multiplying ACRS's current stock price of $14.05 by ACRS's total outstanding shares of 66,683,191.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.